These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22227166)

  • 1. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.
    Geng F; Jiao Z; Dao YJ; Qiu XY; Ding JJ; Shi XJ; Li ZD; Zhong MK
    Clin Chim Acta; 2012 Apr; 413(7-8):683-90. PubMed ID: 22227166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
    Miura M; Kagaya H; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
    Ther Drug Monit; 2008 Oct; 30(5):559-64. PubMed ID: 18695635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
    Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Suzuki T; Habuchi T
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1161-9. PubMed ID: 17906856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
    Lévesque E; Delage R; Benoit-Biancamano MO; Caron P; Bernard O; Couture F; Guillemette C
    Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients.
    Zhang WX; Chen B; Jin Z; Yu Z; Wang X; Chen H; Mao A; Cai W
    Xenobiotica; 2008 Nov; 38(11):1422-36. PubMed ID: 18946804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms in metabolic enzymes and transporters have no impact on mycophenolic acid pharmacokinetics in adult kidney transplant patients co-treated with tacrolimus: A population analysis.
    Yang CL; Sheng CC; Liao GY; Su Y; Feng LJ; Xia Q; Jiao Z; Xu DJ
    J Clin Pharm Ther; 2021 Dec; 46(6):1564-1575. PubMed ID: 34312870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.
    Baldelli S; Merlini S; Perico N; Nicastri A; Cortinovis M; Gotti E; Remuzzi G; Cattaneo D
    Pharmacogenomics; 2007 Sep; 8(9):1127-41. PubMed ID: 17924828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients.
    Xie XC; Li J; Wang HY; Li HL; Liu J; Fu Q; Huang JW; Zhu C; Zhong GP; Wang XD; Sun PP; Huang M; Wang CX; Li JL
    Acta Pharmacol Sin; 2015 May; 36(5):644-50. PubMed ID: 25864649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
    Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies.
    Jiao Z; Zhong JY; Zhang M; Shi XJ; Yu YQ; Lu WY
    Eur J Clin Pharmacol; 2007 Jan; 63(1):27-37. PubMed ID: 17093994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers.
    Lévesque E; Benoit-Biancamano MO; Delage R; Couture F; Guillemette C
    Pharmacogenomics; 2008 Jul; 9(7):869-79. PubMed ID: 18597651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC; van Gelder T; Sombogaard F; Shaw LM; van Hest RM; Mathot RA
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
    Naesens M; Kuypers DR; Streit F; Armstrong VW; Oellerich M; Verbeke K; Vanrenterghem Y
    Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.
    Ting LS; Benoit-Biancamano MO; Bernard O; Riggs KW; Guillemette C; Ensom MH
    Pharmacotherapy; 2010 Nov; 30(11):1097-108. PubMed ID: 20973683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.
    Kim CO; Cho SK; Oh ES; Park MS; Chung JY
    J Cardiovasc Pharmacol; 2012 Jul; 60(1):49-54. PubMed ID: 22494992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients.
    Shipkova M; Armstrong VW; Weber L; Niedmann PD; Wieland E; Haley J; Tönshoff B; Oellerich M;
    Ther Drug Monit; 2002 Jun; 24(3):390-9. PubMed ID: 12021631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
    Kagaya H; Inoue K; Miura M; Satoh S; Saito M; Tada H; Habuchi T; Suzuki T
    Eur J Clin Pharmacol; 2007 Mar; 63(3):279-88. PubMed ID: 17211619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.